Drug
Vernakalant clinical trials
Also written RSD1235, BRINAVESS and Kynapid.
- studies test it
- 16
- open now
- 1
- in phase 3
- 9
- first study started
- 2003
Keep track of what changes. Save the vernakalant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2003 (2)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2017 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
- Phase 3
- 9
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 5
Advanz Pharma (8) · Astellas Pharma Inc (3) · Ottawa Hospital Research Institute (1) · David Filgueiras-Rama (1) · Medical University of Vienna (1) · University of Calgary (1) · Maastricht University Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vernakalant is read from its arms, and is right about nine times in ten.
Testing it · 16
- Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery PatientsNot yet recruitingPhase 3University of CalgaryNCT04748991Written as Vernakalant
- RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency DepartmentCompletedPhase 4Ottawa Hospital Research InstituteNCT04485195Written as Vernakalant
- Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic CurrentsCompletedPhase 4David Filgueiras-RamaNCT03005366Written as Vernakalant
- A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)CompletedPhase 3Advanz PharmaNCT01174160Written as vernakalant hydrochloride
- Vernakalant Versus Ibutilide In Recent-Onset Atrial FibrillationCompletedPhase 4Medical University of ViennaNCT01447862Written as Brinavess (Vernakalant)
- A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)TerminatedPhase 3Advanz PharmaNCT00989001Written as Vernakalant
- A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)WithdrawnPhase 4Advanz PharmaNCT01627106Written as Vernakalant
- Vernakalant Versus Flecainide: Atrial ContractilityStatus unknownPhase 4Maastricht University Medical CenterNCT01646281Written as Vernakalant
- A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial FibrillationCompletedPhase 3Advanz PharmaNCT00668759Written as Vernakalant Injection
- Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter RecurrenceCompletedPhase 2Advanz PharmaNCT00267930Written as Vernakalant (oral)
- Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion StudyCompletedPhase 2Advanz PharmaNCT00526136Written as Vernakalant (oral)
- Study of RSD1235 to Evaluate Safety in Patients With Atrial FibrillationCompletedPhase 3Astellas Pharma IncNCT00281554Written as RSD1235
- Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial FibrillationCompletedPhase 3Advanz PharmaNCT00468767Written as Vernakalant Injection 20 mg/mL
- A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial FlutterCompletedPhase 2/3Advanz PharmaNCT00476112Written as Vernakalant Injection 20 mg/mL
- Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial FlutterCompletedPhase 3Astellas Pharma IncNCT00115791Written as RSD1235
- Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart SurgeryCompletedPhase 3Astellas Pharma IncNCT00125320Written as RSD1235
Codes
What other systems call vernakalant · ClinicalTrials.gg INT005188
- MeSH (NLM) C524581vernakalantOne source NLM
- UNII (FDA) 9G468C8B13VERNAKALANTConfirmed FDA, NLM, Wikidata
- Wikidata Q665725vernakalantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152864VernakalantOne source FDA
- DrugBank DB06217One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524581 | vernakalant | One source NLM |
| UNII (FDA) | 9G468C8B13 | VERNAKALANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q665725 | vernakalant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152864 | Vernakalant | One source FDA |
| DrugBank | DB06217 | — | One source Wikidata |
Also registered as vernakalant hydrochloride (UNII 7G4J1ZD9UQ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.